LIVN Healthcare

LivaNova PLC

$79.90-0.39%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United Kingdom
Market cap: 4.4B USD
Enterprise value: 4.1B USD
Full-time employees: 3,300

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback: less short-term liquidity (current ratio 1.45 vs a peer median of 2.59)less liquidity (current ratio 1.45 vs peers 2.59)
About average: risk (debt, liquidity and share-price swings)risk

Ranks #220 of 1,157 healthcare companies (top 20%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
LivaNova made a profit per share in its latest year after a loss the year before.
Operating margin at a 6-year high. 14% in 2025, the best of the last 6 years.
LivaNova kept 14% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.
Investment surge. Capital spending 5.8% of revenue, up from 2.6% in 2022.
LivaNova is spending 5.8% of revenue on facilities and equipment, up from 2.6% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

StockQuotient Score

66/ 100

Oct 5 66 → Nov 4 66

Valuation

Is the price right?

66/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Stronger than most peers on:

▲ Earnings yield
▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield4.3%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 1.90Sector median: 0.0148 · MAD: 0.0148

EBITDA yield6.1%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsReported value50% base weight · Z-score 0.52Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield3.4%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield30.1%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

82/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 2.7%

Why

Stronger than most peers on:

▲ EPS growth
▲ Revenue growth
▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a loss to a profit33% base weight · Z-score 4.46Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth10.7%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 0.58Sector median: 0.0584 · MAD: 0.0840

Revenue growth12.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.65Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

75/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ ROA
▲ ROIC
▲ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin12.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.47Sector median: 0.0706 · MAD: 0.1217

Return on assets7.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.02Sector median: 0.0166 · MAD: 0.0537

Return on invested capital13.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.87Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin68.1%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity14.2%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Held back by:

▼ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.87

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.72Sector median: 0.6250 · MAD: 0.3380

Current ratio1.45×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.82Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.22×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.00Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about LivaNova

Is LivaNova getting weaker?: Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 66/100 since Oct 28, 2026.
How is LivaNova valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 66/100 against 1,393 healthcare peers. Earnings yield 4.3% vs a peer median of 1.5% (stronger than 73% of peers).Earnings yield 4.3% vs peers 1.5% (stronger than 73% of peers).
Is LivaNova growing?: Yes, faster than most of its peers. Growth scores 82/100 against 1,393 healthcare peers. Revenue growth 12.4% vs a peer median of 6.1% (stronger than 67% of peers).Revenue growth 12.4% vs peers 6.1% (stronger than 67% of peers).
How profitable is LivaNova?: More profitable than most of its peers. Profitability scores 75/100 against 1,393 healthcare peers. Return on assets 7.1% vs a peer median of 1.7% (stronger than 82% of peers).Return on assets 7.1% vs peers 1.7% (stronger than 82% of peers).
How risky is LivaNova?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.45× vs a peer median of 2.59× (weaker than 75% of peers).Current ratio 1.45× vs peers 2.59× (weaker than 75% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	1.4B USD	1.5B USD	+2.7%
Net income (12 months)	107.1M USD	188.5M USD	+76.0%
Operating margin	13.4%	12.7%	−0.7 pts
Free cash flow (12 months)	161.0M USD	148.3M USD	−7.9%
Debt	287.8M USD	293.5M USD	+2.0%
Cash	539.7M USD	516.6M USD	−4.3%
Shares outstanding	54.9M	55.1M	+0.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	68.2%	69.2%	65.5%	68.1%	67.7%	▼ 0.4 pts
Operating margin	-0.1%	-7.5%	-5.9%	10.3%	14.4%	▲ 4.1 pts
Net margin	-13.1%	-8.4%	1.5%	5.0%	-17.5%	▼ 23 pts
Return on assets (ROA)	-6.2%	-3.8%	0.7%	2.5%	-9.3%	▼ 12 pts
Return on equity (ROE)	-10.5%	-7.1%	1.4%	4.8%	-20.2%	▼ 25 pts
Free cash flow margin	7.4%	4.2%	3.5%	10.8%	12.5%	▲ 1.6 pts
Current ratio	0.97×	2.98×	2.95×	2.87×	1.36×	▼ 53%
Quick ratio	0.82×	2.54×	2.51×	2.50×	1.16×	▼ 54%
Debt to equity	0.19×	0.45×	0.46×	0.48×	0.31×	▼ 34%
Interest coverage	-0.02×	-1.59×	-1.16×	2.05×	4.05×	▲ 98%

LIVN price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings

Drawback: less short-term liquidity (current ratio 1.45 vs a peer median of 2.59)less liquidity (current ratio 1.45 vs peers 2.59)

About average: risk (debt, liquidity and share-price swings)risk

Ranks #220 of 1,157 healthcare companies (top 20%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.

LivaNova made a profit per share in its latest year after a loss the year before.

Operating margin at a 6-year high. 14% in 2025, the best of the last 6 years.

LivaNova kept 14% of revenue as operating profit in 2025, its highest in the 6 years of filings we have.

Investment surge. Capital spending 5.8% of revenue, up from 2.6% in 2022.

LivaNova is spending 5.8% of revenue on facilities and equipment, up from 2.6% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

Questions investors ask about LivaNova

Is LivaNova getting weaker?

Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 66/100 since Oct 28, 2026.

How is LivaNova valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 66/100 against 1,393 healthcare peers. Earnings yield 4.3% vs a peer median of 1.5% (stronger than 73% of peers).Earnings yield 4.3% vs peers 1.5% (stronger than 73% of peers).

Is LivaNova growing?

Yes, faster than most of its peers. Growth scores 82/100 against 1,393 healthcare peers. Revenue growth 12.4% vs a peer median of 6.1% (stronger than 67% of peers).Revenue growth 12.4% vs peers 6.1% (stronger than 67% of peers).

How profitable is LivaNova?

More profitable than most of its peers. Profitability scores 75/100 against 1,393 healthcare peers. Return on assets 7.1% vs a peer median of 1.7% (stronger than 82% of peers).Return on assets 7.1% vs peers 1.7% (stronger than 82% of peers).

How risky is LivaNova?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 1.45× vs a peer median of 2.59× (weaker than 75% of peers).Current ratio 1.45× vs peers 2.59× (weaker than 75% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

1.4B USD

1.5B USD

+2.7%

Net income (12 months)

107.1M USD

188.5M USD

+76.0%

Operating margin

13.4%

12.7%

−0.7 pts

Free cash flow (12 months)

161.0M USD

148.3M USD

−7.9%

Debt

287.8M USD

293.5M USD

+2.0%

Cash

539.7M USD

516.6M USD

−4.3%

Shares outstanding

54.9M

55.1M

+0.3%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

68.2%

69.2%

65.5%

68.1%

67.7%

▼ 0.4 pts

Operating margin

-0.1%

-7.5%

-5.9%

10.3%

14.4%

▲ 4.1 pts

Net margin

-13.1%

-8.4%

1.5%

5.0%

-17.5%

▼ 23 pts

Return on assets (ROA)

-6.2%

-3.8%

0.7%

2.5%

-9.3%

▼ 12 pts

Return on equity (ROE)

-10.5%

-7.1%

1.4%

4.8%

-20.2%

▼ 25 pts

Free cash flow margin

7.4%

4.2%

3.5%

10.8%

12.5%

▲ 1.6 pts

Current ratio

0.97×

2.98×

2.95×

2.87×

1.36×

▼ 53%

Quick ratio

0.82×

2.54×

2.51×

2.50×

1.16×

▼ 54%

Debt to equity

0.19×

0.45×

0.46×

0.48×

0.31×

▼ 34%

Interest coverage

-0.02×

-1.59×

-1.16×

2.05×

4.05×

▲ 98%